Tesamorelin Side Effects: How Common, Label Warnings and User Reports

Short answer

In the trials behind the Egrifta label, the most common tesamorelin side effects were injection-site reactions (redness, itching, pain), joint pain, pain in the arms or legs, swelling, muscle aches and tingling or numbness. Most of these come from fluid retention as growth hormone rises and usually ease or resolve after stopping. The label's bigger warnings are higher blood sugar (more people reached the diabetes range than on placebo), a raised IGF-1, allergic reactions in 4%, and caution around cancer. It is contraindicated in active cancer and pregnancy. Peptide Confessions does not publish dosing, timing, injection or sourcing guidance.

How common each side effect was

From the first 26 weeks of the placebo-controlled trials (543 people on tesamorelin, 263 on placebo), all adults with HIV and excess belly fat. Source: Egrifta WR prescribing information (DailyMed, revised March 2025). Last reviewed October 19, 2026.

The label warnings in plain English

• —Blood sugar. Tesamorelin can cause glucose intolerance. The label says to check glucose before starting and periodically, and that people with diabetes may need their medicines adjusted and should be watched for worsening eye disease (retinopathy).
• —IGF-1. It raises IGF-1, a growth factor; the effects of keeping it high for a long time are unknown. Prescribers are told to monitor it and consider stopping if it stays very high, especially when the fat response is weak.
• —Fluid retention. Swelling, joint pain and carpal tunnel syndrome are described as transient or resolving after stopping.
• —Allergic reactions. The label says to stop and get prompt medical attention if one is suspected.
• —Injection-site reactions. These were more common than on placebo.
• —Critical illness. Growth hormone has been linked to higher death rates in acutely critically ill patients, so stopping is advised to be considered in that setting.
• —Steroid replacement. People on glucocorticoid replacement for adrenal insufficiency may need it increased.

Allergic reactions and antibodies

About half of trial patients (50% at 26 weeks) developed antibodies to tesamorelin, and 85% of those who had an allergic reaction had them. The antibodies did not seem to blunt the fat or IGF-1 response. Reactions in the trials were mostly skin-level: itching, redness, flushing, hives and rash.

The most serious stories in our archive are allergic. #107 describes anaphylaxis at the very first injection that needed emergency treatment. #770 had itching, a metallic taste and vomiting, blamed other peptides, then reacted again within seconds on going back to tesamorelin after months of use, struggled to breathe and has a gap in memory. #658 gave it up after developing an allergic reaction. These are individual reports, not rates, and products from unregulated sellers add their own risks; the approved drug and "research" vials are not the same thing.

Does tesamorelin cause cancer?

No study has shown that it does. The caution comes from biology: growth hormone is a growth factor, so the label contraindicates tesamorelin in active cancer, asks for careful evaluation in people with a treated cancer or a benign tumour in the past, and says to stop if cancer comes back. It also notes that people with HIV already have a higher background cancer risk. Lifetime cancer studies in rodents have not been done; standard lab tests found no sign of mutagenic effects. Anyone with a cancer history needs a specialist's input.

Blood sugar in other trials

Glucose effects look small on average but real for some people. Fasting glucose rose slightly in the first weeks of one trial and was not different from placebo by 6 months (Stanley 2014). In 53 people with type 2 diabetes, 12 weeks of tesamorelin did not change insulin response or HbA1c vs placebo (Clemmons 2017, sponsored by the maker), and in a 12-month fatty-liver trial glucose and HbA1c did not differ from placebo (Stanley 2019). The label's 5% vs 1% diabetes-range figure is why monitoring is still advised. #402 asks whether tesamorelin and semaglutide pull blood sugar in opposite directions; that is a question for whoever prescribes them.

Tingling, joint pain and carpal tunnel

Tingling, numbness and joint pain are labelled effects. In the US FDA adverse event database, tesamorelin was one of ten drugs with a strong reporting signal for carpal tunnel syndrome (Mihalache 2025); that shows over-reporting, not how often it happens. In our archive, #380 had whole-body tingling in week one, could not eat solid food for three days, vomited and stopped. #634 describes aching joints and skin that feels like needles for two days after accidentally taking more than intended alongside ipamorelin. #451 later suspected water retention from tesamorelin and creatine was hiding fat loss on the scale.

Long-term side effects

Controlled safety data run to 52 weeks. In people who stayed on it for a year, glucose showed no clinically meaningful change (Falutz 2010), but IGF-1 was still above 2 SDS in 34% at the end, according to the label. The label says long-term cardiovascular safety has not been established. Who should not use it, per the label: people with active cancer, a known allergy to tesamorelin, pregnancy, or a disrupted hypothalamic-pituitary axis (for example after pituitary surgery, head radiation or head trauma). Women-specific points are on tesamorelin for women. Report side effects to a pharmacist or the FDA's MedWatch (Canada Vigilance in Canada).